Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS – Free Report) – Research analysts at HC Wainwright decreased their Q2 2026 EPS estimates for shares of Pelthos Therapeutics in a research note issued on Friday, May 15th. HC Wainwright analyst B. Folkes now anticipates that the company will earn ($4.19) per share for the quarter, down from their previous estimate of ($3.48). HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. The consensus estimate for Pelthos Therapeutics’ current full-year earnings is ($11.35) per share. HC Wainwright also issued estimates for Pelthos Therapeutics’ Q3 2026 earnings at ($3.27) EPS, Q4 2026 earnings at ($3.62) EPS, FY2026 earnings at ($16.43) EPS, FY2027 earnings at ($5.09) EPS, FY2028 earnings at $5.97 EPS, FY2029 earnings at $10.32 EPS and FY2030 earnings at $13.50 EPS.
Pelthos Therapeutics (NYSEAMERICAN:PTHS – Get Free Report) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($3.09) EPS for the quarter. The firm had revenue of $10.91 million for the quarter.
Read Our Latest Research Report on PTHS
Pelthos Therapeutics Trading Down 2.1%
Shares of NYSEAMERICAN:PTHS opened at $26.15 on Tuesday. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.86 and a current ratio of 2.79. The firm has a 50 day moving average price of $23.61. The stock has a market cap of $91.00 million, a P/E ratio of -1.27 and a beta of 3.29. Pelthos Therapeutics has a 52 week low of $9.00 and a 52 week high of $54.29.
Institutional Trading of Pelthos Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in PTHS. Ikarian Capital LLC raised its position in shares of Pelthos Therapeutics by 309.5% in the fourth quarter. Ikarian Capital LLC now owns 255,758 shares of the company’s stock valued at $7,928,000 after buying an additional 193,307 shares during the last quarter. J. Goldman & Co LP acquired a new position in shares of Pelthos Therapeutics in the fourth quarter valued at approximately $2,418,000. Boothbay Fund Management LLC raised its position in shares of Pelthos Therapeutics by 279.8% in the fourth quarter. Boothbay Fund Management LLC now owns 80,680 shares of the company’s stock valued at $2,501,000 after buying an additional 59,435 shares during the last quarter. Cantor Fitzgerald L. P. acquired a new position in shares of Pelthos Therapeutics in the fourth quarter valued at approximately $1,085,000. Finally, Diadema Partners LP raised its position in shares of Pelthos Therapeutics by 138.1% in the fourth quarter. Diadema Partners LP now owns 25,000 shares of the company’s stock valued at $775,000 after buying an additional 14,502 shares during the last quarter. 77.96% of the stock is currently owned by hedge funds and other institutional investors.
Pelthos Therapeutics Company Profile
We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).
Further Reading
- Five stocks we like better than Pelthos Therapeutics
- Why Trump’s Amazon Stock Sale May Not Matter at All
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
Receive News & Ratings for Pelthos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pelthos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
